Image

Enhanced Vision and Imaging Tests for Enabling Treatment Trials in Early and Intermediate AMD

Enhanced Vision and Imaging Tests for Enabling Treatment Trials in Early and Intermediate AMD

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

This monocentric prospective longitudinal observational study will validate fundus-tracked dark adaptometry as an endpoint for future treatment trials in early and intermediate age-related macular degeneration (AMD). The study will characterize normative cone- and rod-mediated dark adaptation parameters in healthy volunteers, assess test-retest reliability, quantify sensitivity to change over time, evaluate diagnostic and prognostic validity against AMD stage and structural progression, and investigate imaging-, biomarker-, and genetics-based determinants of impaired dark adaptation.

Description

Age-related macular degeneration (AMD) is a major cause of visual impairment. Treatments currently exist only for late-stage disease, while early and intermediate AMD lack validated functional endpoints suitable for treatment trials. This study will validate fundus-tracked dark adaptometry by determining its diagnostic accuracy, within-visit and between-visit repeatability, and longitudinal sensitivity to change. In addition, multimodal retinal imaging, blood-based biomarkers, metabolomics, proteomics, and AMD-related genetic variants will be assessed for their ability to predict or explain delayed dark adaptation. Healthy volunteers will undergo 2 visits (baseline and month 2); participants with early or intermediate AMD will undergo 3 visits (baseline, month 2, and month 18).

Eligibility

Inclusion Criteria:

  • Written informed consent.
  • All biological sexes and gender identities.
  • Age \>=18 years for healthy volunteers; age \>=55 years for participants with AMD.
  • Ability to understand German or English sufficiently for study information and procedures.

Additional Inclusion Criteria by Cohort:

Healthy Volunteers:

\- No drusen \>63 um and no subretinal drusenoid deposits in either eye.

Early AMD:

\- Study eye with drusen \>63 um but \<125 um and no pigmentary changes.

Intermediate AMD:

\- Study eye with drusen \>125 um and/or pigmentary changes.

Exclusion Criteria:

  • Claustrophobia relevant to dark-adaptation procedures.
  • Hypersensitivity to indocyanine green or sodium iodide, iodine allergy, or hyperthyroidism.
  • Known pregnancy.
  • Study eye history of ocular surgery other than cataract surgery, YAG capsulotomy, or laser retinopexy.
  • Ocular disease in the study eye that could affect visual function testing in the opinion of the investigators.
  • Medical conditions or planned operations that could interfere with follow-up.
  • Inability to comply with study procedures or insufficient language skills in the study language.
  • Inability to provide informed consent.

Study details
    Age - Related Macular Degeneration (AMD)

NCT07515521

Maximilian Pfau

13 May 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.